Page 8 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

PMBCL: Postremission, Patients May Safely Skip Radiation

Radiation therapy may be safely omitted for patients with primary mediastinal B-cell lymphoma (PMBCL) who achieved a complete metabolic response after immunochemotherapy. ....

United States , United Kingdom , Ann Arbor , Julier Gralow , Coreyw Speers , Emanuele Zucca , Celgene Incyte , University Of Michigan Hospital , Swiss National Science Foundation , Cancer Research United Kingdom , American Society Of Clinical Oncology , Swiss Cancer League , Oncology Institute Of Southern Switzerland , Oncology Institute , Southern Switzerland , American Society , Clinical Oncology , Michigan Hospital , Swiss National Science , Celltrion Healthcare , Non Hodgkins Lymphoma , Primary Mediastinalb Cell Lymphoma , Radiation Oncology , Lung Cancer , Ung Carcinoma , Ancer Lung ,

EULAR SSc Recommendations Now Include Immunosuppressants

The update to 2017 recommendations include targeted synthetic and biologic disease-modifying antirheumatic drugs for the first time. ....

Ariane Herrick , European Alliance Of Associations , European Congress , University Of Manchester England , Boehringer Ingelheim , European Alliance , Del Galdo , Leeds Teaching Hospital , Scleroderma Trials , Crest Syndrome , Biologic Therapy , Pulmonary Hypertension , Systemic Sclerosis , Diffuse Scleroderma , Interstitial Lung Disease , Heart Failure , Lung Fibrosis , Pulmonary Fibrosis , Ibrosis Pulmonary , Monoclonal Antibody , Antineoplastic Drug , Nti Cancer Agents ,

Chemo Avoidance Pays Off for Some Women With HER2+ Early BC

In the PHERGAIN trial, nearly all patients who were diverted from chemotherapy prior to surgery for HER2-positive early breast cancer survived without cancer recurrence for 3 years. ....

United States , Javier Cort , Kevin Kalinsky , American Society Of Clinical Oncology , Emory University Hospital , Cajal University Hospital , American Society , Clinical Oncology , Lancet Oncology , Breast Cancer , Alignant Breast Neoplasm , Biologic Therapy , Alignant Neoplasia , Antineoplastic Drug , Nti Cancer Agents , Targeted Therapy , Genomic Medicine , Edicine Genomic , Humanized Monoclonal Antibody , Hormone The ,

FDA Approves New Indication for Avapritinib

Avapritinib (AYVAKIT) is now approved to treat adults with indolent systemic mastocytosis. ....

Judith Kain Emmel , Blueprint Medicines Corp , Drug Administration , Mast Cell Disease Society , Kain Emmel , Lysosomal Storage Disease , Systemic Mastocytosis , Peripheral Edema , Bone Marrow , Platelet Growth Factor , Platelet Derived Growth Factor , Tyrosine Kinase Inhibitor , Biologic Therapy , Gastrointestinal Stromal Tumor , Umor Gastrointestinal Stromal , Hematologic Disorders , I Cell Disease , Ucolipidosis T ,

DLBCL: Major New Treatment Breakthroughs

Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL. ....

United States , Jason Westin , Charalambos Andreadis , Kieron Dunleavy , Drug Administration , Md Anderson Cancer Center , International Prognostic Indices , Jamie Raskin , San Francisco , Helen Diller Family Comprehensive Cancer , Lombardi Comprehensive Cancer Center , Georgetown University Hospital , Medstar Georgetown Lymphoma , Cancer Center , Congressman Raskin , Non Hodgkins Lymphoma , Biologic Therapy , Diffuse Large Cell Lymphoma , Chimeric Antigen Receptort Cell Therapy , Chimeric Antigen Receptors , Himeric Immunoreceptors , Himerict Cell Receptors , Rtificialt Cell Receptors , Ar T , Malignant Lymphoma , B Cell Lymphoma ,